Opin vísindi

Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients

Show simple item record

dc.contributor Háskóli Íslands
dc.contributor University of Iceland
dc.contributor.author Udumyan, Ruzan
dc.contributor.author Montgomery, Scott
dc.contributor.author Duberg, Ann-Sofi
dc.contributor.author Fang, Fang
dc.contributor.author Valdimarsdottir, Unnur
dc.contributor.author Ekbom, Anders
dc.contributor.author Smedby, Karin E.
dc.contributor.author Fall, Katja
dc.date.accessioned 2021-01-12T11:45:13Z
dc.date.available 2021-01-12T11:45:13Z
dc.date.issued 2020-05-03
dc.identifier.citation Ruzan Udumyan, Scott Montgomery, Ann-Sofi Duberg, Fang Fang, Unnur Valdimarsdottir, Anders Ekbom, Karin E. Smedby & Katja Fall (2020) Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients, Scandinavian Journal of Gastroenterology, 55:5, 597-605, DOI: 10.1080/00365521.2020.1762919
dc.identifier.issn 0036-5521
dc.identifier.issn 1502-7708 (eISSN)
dc.identifier.uri https://hdl.handle.net/20.500.11815/2350
dc.description Publisher's version (útgefin grein)
dc.description.abstract Background: β-adrenergic signaling has been implicated in the pathology of hepatocellular carcinoma (HCC), but the evidence from clinical studies is limited. In this national population-based cohort study, we investigated the possible association of β-adrenergic receptor blockers and cancer-specific mortality among patients with primary HCC diagnosed in Sweden between 2006 and 2014. Methods: Patients were identified from the Swedish Cancer Register (n = 2104) and followed until 31 December 2015. We used Cox regression to evaluate the association of β-blockers dispensed within 90 days prior to cancer diagnosis, ascertained from the national Prescribed Drug Register, with liver cancer mortality identified from the Cause of Death Register, while controlling for socio-demographic factors, tumor characteristics, comorbidity, other medications and treatment procedures. Results: Over a median follow-up of 9.9 months, 1601 patients died (of whom 1309 from liver cancer). Compared with non-use, β-blocker use at cancer diagnosis [n = 714 (predominantly prevalent use, 93%)] was associated with lower liver cancer mortality [0.82 (0.72–0.94); p =.005]. Statistically significant associations were observed for non-selective [0.71 (0.55–0.91); p =.006], β1-receptor selective [0.86 [0.75–1.00); p =.049] and lipophilic [0.78 (0.67–0.90); p =.001] β-blockers. No association was observed for hydrophilic β-blockers [1.01 (0.80–1.28); p =.906] or other antihypertensive medications. Further analysis suggested that the observed lower liver cancer mortality rate was limited to patients with localized disease at diagnosis [0.82 (0.67–1.01); p =.062]. Conclusion: β-blocker use was associated with lower liver cancer mortality rate in this national cohort of patients with HCC. A higher-magnitude inverse association was observed in relation to non-selective β-blocker use.
dc.description.sponsorship This work was supported by a grant from the Swedish Cancer Society (CAN 2013/650). Dr Karin E. Smedby has research funding from Janssen.
dc.format.extent 597-605
dc.language.iso en
dc.publisher Informa UK Limited
dc.relation.ispartofseries Scandinavian Journal of Gastroenterology;55(5)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Beta-adrenergic signaling
dc.subject Non-selective beta-blockers
dc.subject Register-based cohort study
dc.subject Selective beta-blockers
dc.subject Survival analysis
dc.subject Lifrarkrabbamein
dc.subject Lyfjagjöf
dc.subject Lífslíkur
dc.title Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients
dc.type info:eu-repo/semantics/article
dcterms.license This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
dc.description.version Peer Reviewed
dc.identifier.journal Scandinavian Journal of Gastroenterology
dc.identifier.doi 10.1080/00365521.2020.1762919
dc.relation.url https://www.tandfonline.com/doi/pdf/10.1080/00365521.2020.1762919
dc.contributor.department Miðstöð í lýðheilsuvísindum (HÍ)
dc.contributor.department The Centre of Public Health Sciences (UI)
dc.contributor.school Heilbrigðisvísindasvið (HÍ)
dc.contributor.school School of Health Sciences (UI)

Files in this item

This item appears in the following Collection(s)

Show simple item record